posted on 2022-02-22, 20:43authored byJeppe K. Larsen, Magnus R. Larsen, Jesper B. Birk, Dorte E. Steenberg, Janne R. Hingst, Kurt Højlund, Alexandra Chadt, Hadi Al-Hasani, Atul S. Deshmukh, Jørgen F.P. Wojtaszewski, Rasmus Kjøbsted
Insulin-stimulated muscle glucose uptake is a key process in glycemic
control. This process depends on the redistribution of glucose transporters to
the surface membrane, a process which involves regulatory proteins such as TBC1D1
and TBC1D4. Accordingly, a TBC1D4 loss-of-function
mutation in human skeletal muscle is associated with increased risk of type 2
diabetes, and observations from carriers of a TBC1D1 variant associate this
protein to a severe obesity phenotype. Here, we identified interactors of the
endogenous TBC1D4 in human skeletal muscle by an unbiased proteomics approach.
We detected 76 proteins as candidate TBC1D4 interactors. The binding of 12 of
these interactors were regulated by insulin, including proteins known to be involved
in glucose metabolism (e.g. 14-3-3 proteins and ACTN4). TBC1D1 also
co-precipitated with TBC1D4 and vice versa in both human and mouse skeletal
muscle. This interaction was not regulated by insulin nor exercise in young,
healthy, lean individuals. Similarly, the exercise- and insulin-regulated
phosphorylation of the TBC1D1-TBC1D4 complex was intact. In contrast, we
observed an altered interaction as well as compromised insulin-stimulated
phospho-regulation of the TBC1D1-TBC1D4 complex in muscle of obese individuals
with type 2 diabetes. Altogether, we provide a repository of TBC1D4 interactors
in human and mouse skeletal muscle, which serve as potential regulators of
TBC1D4 function and, thus, insulin-stimulated glucose uptake in human skeletal
muscle.
Funding
This work was supported by grants from the Danish Council for Independent Research (FSS: 610-00498B) and the Novo Nordisk Foundation (NNF21OC0070370) given to JFPW. This work was also supported by a postdoctoral research fellow grant to R.K. from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation (grant number NNF17SA0031406). The proteomics analysis and ASD were supported by the Novo Nordisk Foundation (NNF14CC001 and NNF18CC0034900).